The Evaluation of New Antiarrhythmic Drugs: Proceedings of the Symposium on How to Evaluate a New Antiarrhythmic Drug: The Evaluation of New Antiarrhythmic Agents for the Treatment of Ventricular Arrhythmias, held at Philadelphia, Pennsylvania, October 8–9, 1980: Developments in Cardiovascular Medicine, cartea 11
Editat de J. Morganroth, E. Neil Moore, L.S. Dreifus, E.L. Michelsonen Limba Engleză Paperback – 22 noi 2011
Din seria Developments in Cardiovascular Medicine
- 5% Preț: 1484.50 lei
- 5% Preț: 375.17 lei
- 5% Preț: 354.10 lei
- 5% Preț: 1419.03 lei
- 5% Preț: 376.43 lei
- 5% Preț: 1098.27 lei
- 5% Preț: 1438.38 lei
- 5% Preț: 376.78 lei
- 5% Preț: 368.37 lei
- 5% Preț: 380.25 lei
- 5% Preț: 2117.58 lei
- 5% Preț: 367.28 lei
- 5% Preț: 366.56 lei
- 5% Preț: 370.94 lei
- 5% Preț: 783.18 lei
- 5% Preț: 713.18 lei
- 5% Preț: 1098.27 lei
- 5% Preț: 375.49 lei
- 5% Preț: 373.47 lei
- 5% Preț: 723.93 lei
- 5% Preț: 1104.13 lei
- 5% Preț: 2117.20 lei
- 5% Preț: 716.09 lei
- 5% Preț: 372.03 lei
- 5% Preț: 722.33 lei
- 5% Preț: 660.07 lei
- 5% Preț: 375.34 lei
- 5% Preț: 1423.22 lei
- 5% Preț: 715.35 lei
- 5% Preț: 790.69 lei
- 5% Preț: 720.68 lei
- 5% Preț: 3185.49 lei
- 5% Preț: 1418.27 lei
- 5% Preț: 784.64 lei
- 5% Preț: 714.63 lei
- 5% Preț: 370.74 lei
- 5% Preț: 376.22 lei
- 5% Preț: 660.85 lei
- 5% Preț: 368.37 lei
Preț: 371.10 lei
Preț vechi: 390.63 lei
-5% Nou
Puncte Express: 557
Preț estimativ în valută:
71.02€ • 73.69$ • 59.36£
71.02€ • 73.69$ • 59.36£
Carte tipărită la comandă
Livrare economică 15-29 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789400982727
ISBN-10: 9400982720
Pagini: 340
Ilustrații: 340 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.48 kg
Ediția:Softcover reprint of the original 1st ed. 1981
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Cardiovascular Medicine
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9400982720
Pagini: 340
Ilustrații: 340 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.48 kg
Ediția:Softcover reprint of the original 1st ed. 1981
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Cardiovascular Medicine
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- Pre-Clinical Evaluation of a New Antiarrhythmic Agent.- Relationships between effects on cardiac electrophysiology and antiarrhythmic efficacy.- What animal models should be used to define antiarrhythmic efficacy: acute dog models?.- Description of chronic canine myocardial infaction models suitable for the electropharmacologic evaluation of new antiarrhythmic drugs.- Non-canine animal models for evaluating antiarrhythmic efficacy General Group Discussion: Animal Models.- Defining the pharmacodynamics and pharmacokinetics of new antiarrhythmic drugs General Group Discussion: Pharmacology.- Chronic Studies in Patients with Non-Hemodynamically Significant Ventricular Arrhythmics.- How should Holter monitoring analysis be performed?.- Long-term ambulatory electrocardiographic recording in the determination of efficacy of new antiarrhythmic agents.- Evaluation of antiarrhythmic drugs. Should the Lown classification be used as a measure of efficacy?.- General Group Discussion: Holter Monitoring.- Study Designs: Chronic Patients.- New means of evaluating antiarrhythmic drugs.- Parallel or crossover designs in evaluation of antiarrhythmic therapy.- General Group Discussion: Study Designs: Chronic Patients.- Acute Studies in Patients with Hemodynamically Significant Significant Ventricular Arrhythmias.- Acute drug testing as a part of a systematic approach to antiarrhythmic drug therapy.- What is the role of electrophysiology in drug testing? General Group Discussion: Electrophysiology.- What should the study design be to test new antiarrhythmic drugs in patients with acute myocardial infarction, digitalis toxicityand other acute problems General Group Discussion: Study Designs in Acute Patients.- Special Considerations.- What baseline electrophysiologic data should be obtained (plus discussion).- Assessment of the hemodynamic and inotropic effects of antiarrhythmic drugs (plus discussion).- Evaluation of drug treatment in supraventricular arrhythmias (plus discussion).- How should long-term safety of a new antiarrhythmic drug be defined (plus discussion).- How should one manage emergency drug requests and their data (puls discussion).- How does one evaluate and use outside U.S.A. data in the new drug application (plus discussion).